Alphatec Holdings, Inc. (ATEC): Results of Operations and Financial Condition
Alphatec Holdings, Inc. (ATEC) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 atec-ex99_1.htm EX-99.1 EX-99.1 Exhibit 99.1 ATEC Reports Second Quarter Financial Results Total revenue of $214 million, up 15% year-over-year Surgical revenue of $196 million increased 17%, driven by 20% case volume growth Company reaffirms 2026 revenue outlook CARLSB
How this was made
The 30-second read
Why it matters
Traders can update models around profitability and cash flow expectations using the raised adjusted EBITDA guidance and the reported Q2 margin and free cash flow positivity, while monitoring whether GAAP losses persist.
Market read
A primary earnings-and-guidance disclosure with specific quarterly metrics and a guidance increase for adjusted EBITDA, likely driving near-term repricing versus prior expectations.
What to watch
The outlook is described as reaffirmed for revenue, so the key debate is whether case volume and surgeon user growth can sustain margins and free cash flow without additional cost pressure or litigation impacts.
Background
The filing is an SEC Form 8-K (Item 2.02) with Exhibit 99.1 reporting Alphatec’s Q2 2026 results and full-year outlook updates.
Ticker impact
Alphatec reported Q2 revenue of $214M, surgical revenue up 17%, and reaffirmed 2026 revenue while raising adjusted EBITDA to ~$140M.
Likely positive bias for the stock on guidance-updated profitability expectations, with follow-through dependent on whether investors focus on EBITDA margin expansion and free cash flow positivity.
This is a primary SEC filing with specific, time-stamped financial results and a guidance increase (adjusted EBITDA from ~$134M to ~$140M) alongside reaffirmed revenue outlook.
Market effects
Spine-surgery device and EOS-adjacent medtech names may see read-across interest if investors treat ATEC’s surgeon adoption and margin expansion as a demand signal.
Limited direct regional spillover; primarily a US small/mid-cap medtech sentiment driver.
Low global relevance beyond medtech investor sentiment for spine procedure technology adoption.
Counterpoint
Investors may discount the EBITDA raise if they view non-GAAP metrics and litigation-related adjustments as masking underlying GAAP earnings pressure (GAAP net loss was ($26)M in Q2).
Key entities
- companyAlphatec Holdings, Inc.
Spine-focused provider reporting Q2 results and reaffirming 2026 revenue while increasing adjusted EBITDA guidance.
- executivePat Miles
Chairman and CEO quoted on case volume growth, surgeon adoption, and long-term value creation.
